{"prompt": "['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Table 8:', 'Restricted Medications Associated with an Increased Risk of Liver Injury', 'Medications known to be associated with drug-induced liver injury', 'Allopurinol', 'Interferon beta', 'Amiodarone', 'Isoniazid', 'Amoxicillin-clavulanate', 'Methyldopa', 'Anabolic steroids', 'Minocycline', 'Atorvastatin', 'Nevirapine', 'Carbamazepine', 'Nimesulide', 'Chlorpromazine', 'Nitrofurantoin', 'Oral contraceptives', 'Propylthiouracil', 'Dantrolene', 'Quinidine', 'Diclofenac', 'Pyrazinamide', 'Didanosine', 'Simvastatin', 'Disulfiram', 'Sulfamethoxazole/Trimethoprim', 'Flucloxacillin', 'Sulfonamides', 'Halothane', 'Sulindac', 'Hydralazine', 'Telithromycin', 'Ibuprofen', 'Ticlopidine', 'Interferon alpha/Peginterferon', 'Valproate', 'Source: Bj\u00f6rnsson, 2016.', 'GB001 is metabolized at least in part by CYP3A4, hence the need to restrict the usage of known', 'CYP3A4 inducers and inhibitors. Thus, the following is a non-exhaustive list of medications', '(Table! 9) and drink/food (Table 10) which may inhibit or induce CYP3A4 activities that will be', 'prohibited 14 days prior to randomization through the safety Follow-up visit.', 'A non-exhaustive list of prohibited medications and drinks/food to prevent potential metabolic', 'drug-drug interactions is incorporated into Table 9 and Table 10 and also will be provided in the', 'Study Reference Manual.', '75', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Table 9:', 'Prohibited Medications Associated with CYP3A4 Induction or Inhibition', 'Generic Name', 'Brand Name', 'amprenavir', 'Agenerase', 'aprepitant', 'Emend', 'armodafinil', 'Nuvigil', 'atazanavir', 'Reyataz', 'boceprevir', 'Victrelis', 'bosentan', 'Tracleer', 'carbamazepine', 'Tegretol, Biston, Calepsin, Carbatrol, Epitol,', 'Equetro, Finlepsin, Sirtal, Stazepine, Telesmin,', 'Teril, Timonil, Trimonil, Epimaz, and others', 'chloramphenicol', 'Chloramycetin', 'ciprofloxacin', 'Cipro, Cipro I.V., Cipro XR, Cipro Cystitis Pack', 'clarithromycin', 'Biaxin, Klaricid, Klabax, Claripen, Claridar,', 'Fromilid, and others', 'conivaptan', 'Vaprisol', 'crizotinib', 'Xalkori', 'cyproterone', 'Androcur, Cyprostat, Cyproteron, Procur,', 'Cyprone, Cyprohexal, Ciproterona,', 'Cyproteronum, Neoproxil, Siterone', 'delavirdine', 'Rescriptor', 'dexamethasone', 'Decadron, Dexasone, Hexadrol', 'diethyl-dithiocarbamate', 'Disulfiram, Antabuse', 'dihydroergotamine', 'DHE 45', 'diltiazem', 'Cardizem, Tiazac, Dilacor, Cartia', 'efavirenz', 'Sustiva, Stocrin', 'ergotamine', 'Ergormar, Cafergot', 'erythromycin', 'Robimycin, Ery-Tab, EryPed, Erythrocin, and', 'others', 'etravirine', 'Intelence', 'felbamate', 'Felbatol', 'fluconazole', 'Diflucan, Trican, and others', 'fosamprenavir', 'Lexiva', '76', 'CONFIDENTIAL']['GB001, Inc.', 'GB001', 'Protocol GB001-2101', 'Version 5.0, 16 Apr 2020', 'Table 9:', 'Prohibited Medications Associated with CYP3A4 Induction or Inhibition', '(Continued)', 'Generic Name', 'Brand Name', 'gestodene', 'Femoden, Femodene, Femodette, Gynera, and', 'others', 'dexamathasone', 'Decadron, Dexasone, Hexadrol', 'methylprednisolone', 'Medrol, Depo Medrol', 'prednisone', 'Deltasone, Rayos', 'prednisolone', 'Depo Medrol, Flo-Pred', 'griseofulvin', 'Grisovin', 'imatinib', 'Gleevec', 'indinavir', 'Crixivan', 'isavuconazole', 'Cresemba', 'isoniazid', 'Nydrazid', 'itraconazole', 'Sporanox', 'ketoconazole', 'Nizoral', 'lopinavir/ritonavir', 'Kaletra', 'mibefradil', 'Posicor', 'mifepristone', 'Mifeprex', 'modafinil', 'Provigil, Alertec, Modavigil', 'nafcillin', 'Unipen, Nallpen,Nafcil', 'nefazodone', 'Serzone, Nefadar', 'nelfinavir', 'Viracept', 'nevirapine', 'Viramune', 'oxcarbazepine', 'Trileptal', 'phenobarbital', 'Donnatal, Nembutal, and others', 'phenytoin', 'Phenytek, Dilantin, and others', 'fosphenytoin', 'Cerebyx, Prodilantin', 'posaconazole', 'Noxafil', 'primidone', 'Mysoline', 'quinupristin/dalfopristin', 'Synercid', 'rifabutin', 'Mycobutin', '77', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}